Cargando…

Chemoimmunotherapy with rituximab, cyclophosphamide and prednisolone in IgM paraproteinemic neuropathy: evidence of sustained improvement in electrophysiological, serological and functional outcomes

Detalles Bibliográficos
Autores principales:	Colchester, Nancy T. H., Allen, David, Katifi, Haider A., Burt, Tracy, Lown, Robert N., Pinto, Ashwin A., Duncombe, Andrew S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2020
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776249/ https://www.ncbi.nlm.nih.gov/pubmed/32354875 http://dx.doi.org/10.3324/haematol.2019.243139

Ejemplares similares

Glioblastoma, IDH-wildtype: A New Association with IgM Paraproteinaemic Neuropathy?
por: Lewis, Dana M., et al.
Publicado: (2022)

Paraproteinemic neuropathy: a practical review
por: Rison, Richard A., et al.
Publicado: (2016)

Clinicopathological analysis of primary refractory diffuse large B‐cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy
por: Suzuki, Tomotaka, et al.
Publicado: (2021)

Multimodal imaging in paraproteinemic keratopathy
por: Pasricha, Neel D, et al.
Publicado: (2020)

Cyclophosphamide/prednisolone/rituximab: Nosocomial COVID-19 infection: case report
Publicado: (2020)

Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma
por: Hornberger, John, et al.
Publicado: (2008)

Intratumoral T‐cell receptor repertoire is predictive of interim PET scan results in patients with diffuse large B‐cell lymphoma treated with rituximab/cyclophosphamide/doxorubicin/prednisolone/vincristine (R‐CHOP) chemoimmunotherapy
por: Shanavas, Mohamed, et al.
Publicado: (2021)

Diagnosing Paraproteinemic Keratopathy: A Case Report
por: Mok, Eugenie, et al.
Publicado: (2021)

Anemia Is a Novel Predictive Factor for the Onset of Severe Chemotherapy-Induced Peripheral Neuropathy in Lymphoma Patients Receiving Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone Therapy
por: Saito, Takashi, et al.
Publicado: (2019)

Gray zone lymphoma effectively treated with cyclophosphamide, doxorubicin, vincristine, prednisolone, and rituximab chemotherapy: A case report
por: Hojo, Nobumasa, et al.
Publicado: (2022)

Multi‐drug Combination Therapy with Vincristine‐Melphalan‐Cyclophosphamide‐Prednisolone Was More Effective than Cyclophosphamide‐Prednisolone in Stage III Myeloma
por: Shimizu, Kazuyuki, et al.
Publicado: (1990)

Repeated treatments with rituximab in a patient with amyloid-like IgM deposition neuropathy
por: Kadoya, Masato, et al.
Publicado: (2016)

Analysis of Data on Fludarabine, Cyclophosphamide, and Rituximab Chemoimmunotherapy for Chronic Lymphocytic Leukemia Shows High Patient Heterogeneity and the Need for More Consideration of Individualized Treatment
por: Xu, Xiaoli, et al.
Publicado: (2022)

Recurrence of paraproteinemic keratopathy after penetrating keratoplasty and its assessment with confocal microscopy
por: Wasielica-Poslednik, J., et al.
Publicado: (2018)

Cyclophosphamide/methylprednisolone/prednisolone: Multiple infections: case report
Publicado: (2021)

Chemoimmunotherapy for advanced gastrointestinal carcinomas: A successful combination of gene therapy and cyclophosphamide
por: Malvicini, Mariana, et al.
Publicado: (2012)

Diffuse large B-cell lymphoma: 10 years' real-world clinical experience with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisolone
por: Horvat, Matej, et al.
Publicado: (2018)

The Elevation of Cardio-Ankle Vascular Index in a Patient With Malignant Lymphoma Treated With a Combination Therapy of Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone
por: Shimizu, Naomi, et al.
Publicado: (2017)

Delayed COVID-19 Respiratory Failure in Patients with Lymphoma on Rituximab-based Chemoimmunotherapy
por: Hoffmann, Marc S., et al.
Publicado: (2021)

Obinutuzumab, a potent anti–B-cell agent, for rituximab-unresponsive IgM anti-MAG neuropathy
por: Rakocevic, Goran, et al.
Publicado: (2018)

Effective Chemoimmunotherapy with Anti-TGFβ Antibody and Cyclophosphamide in a Mouse Model of Breast Cancer
por: Chen, Xin, et al.
Publicado: (2014)

What Influences the Choice of Ibrutinib–Rituximab vs Classic Chemoimmunotherapy for Chronic Lymphocytic Leukemia?
por: Bravaccini, Sara, et al.
Publicado: (2020)

Treatment response to cyclophosphamide, rituximab, and bortezomib in chronic immune-mediated sensorimotor neuropathies: a retrospective cohort study
por: Motte, Jeremias, et al.
Publicado: (2021)

Recurrence of paraproteinemic crystalline keratopathy after corneal transplantation: A case of monoclonal gammopathy of ocular significance
por: Nobacht, Siamak, et al.
Publicado: (2020)

Successful treatment of recurrent follicular B-cell lymphoma with clarithromycin, prednisolone, and cyclophosphamide
por: Ohe, Masashi, et al.
Publicado: (2013)

Efficacy of chemoimmunotherapy with cyclophosphamide, interleukin-2 and lymphokine activated killer cells in an intraperitoneal murine tumour model.
por: Eggermont, A. M., et al.
Publicado: (1988)

Methotrexate/prednisolone/rituximab: COVID-19 pneumonia: 2 case reports
Publicado: (2021)

Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial
por: Shanafelt, Tait D., et al.
Publicado: (2022)

Pulmonary intravascular large B-cell lymphoma successfully treated with rituximab, cyclophosphamide, vincristine, doxorubicin and prednisolone immunochemotherapy: Report of a patient surviving for over 1 year
por: Nishii-Ito, Shizuka, et al.
Publicado: (2016)

Human Herpesvirus 8–Unrelated Primary Effusion Lymphoma–Like Lymphoma in an Elderly Korean Patient with a Good Response to Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone
por: Shin, Junghoon, et al.
Publicado: (2017)

MUKtwelve protocol: a phase II randomised, controlled, open, parallel group, multicentre trial of selinexor, cyclophosphamide and prednisolone (SCP) versus cyclophosphamide and prednisolone (CP) in patients with relapsed or refractory multiple myeloma
por: Kendall, Jessica, et al.
Publicado: (2022)

Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2- lymphocytes
Publicado: (1981)

Cyclophosphamide/rituximab: COVID-19 infection: case report
Publicado: (2021)

Autologous peripheral blood stem cell mobilization following dose-adjusted cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy alone or in combination with rituximab in treating high-risk non-Hodgkin’s lymphoma
por: Shi, Yuankai, et al.
Publicado: (2015)

Methotrexate, cytarabine, thiotepa and rituximab (MATRix) chemoimmunotherapy for primary central nervous system lymphoma: a Toronto experience
por: Suleman, Adam, et al.
Publicado: (2022)

Intravenous cyclophosphamide and oral prednisolone is a safe and effective treatment option for idiopathic membranous nephropathy
por: Mathrani, Vinod, et al.
Publicado: (2017)

Paraproteinemic keratopathy in monoclonal gammopathy of undetermined significance treated with primary keratoprosthesis: Case report, histopathologic findings, and world literature review
por: Chiang, Homer H., et al.
Publicado: (2017)

Prednisolone/rituximab: COVID-19 and SARS-CoV-2 pneumonia: case report
Publicado: (2021)

Mycophenolate-mofetil/prednisolone/rituximab: Treatment-related osteopenia and candidiasis: 7 case reports
Publicado: (2022)

Progressive outer retinal necrosis after rituximab and cyclophosphamide therapy
por: Dogra, Mohit, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_hiptdlkuk3nsujonb4k3a8ub6l